Integrated care pathways in mental health: The need for the ‘human touch’

International Journal of Care Pathways

Volumn 6, Issue 3, 2002, Pages 108-114

  Peet, Malcolm ^a   Wakefield, Susan ^a  

^a Integrated Care Pathways Co ordinator   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PLACEBO;

ANXIETY DISORDER; ARTICLE; DEPRESSION; DOCTOR PATIENT RELATION; HUMAN RELATION; MENTAL HEALTH CARE; QUESTIONNAIRE;

EID: 0036922388     PISSN: 20404026     EISSN: None     Source Type: Journal    
DOI: 10.1177/147322970200600303     Document Type: Article

References (44)

1. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. European Neuropsychopharmacology 2001; 11: 173–180
2. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? International Journal of Neuropsychopharmacology 2002; 5: 193–197
3. Thase ME, Friedman ES, Berman SR, Fasiczka AL, Lis JA, Howland RH, Simons AD. Is cognitive behaviour therapy just a ‘nonspecific’ intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behaviour therapy or supportive counselling and pill placebo. Journal of Affective Disorders 2000; 57: 63–71
4. Johnstone EC, Deaking JF, Lawler P, Frith CD, Stevens M, McPherson K, Crow TJ. The Northwick Park electroconvulsive therapy trial. Lancet 1982; 2: 1317–1320
5. Brugha TS, Bebbington PE, MacCarthy E, Stuart E, Wykes T. Antidepressants may not assist recovery in practice: a naturalistic prospective study. Acta Psychiatrica Scandinavica 1992; 86: 5–11
6. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA. The functional neuroanatomy of the placebo effects. American Journal of Psychiatry 2002; 159: 728–737
7. Leuchter AF, Cook IA, Witte EA, Morgan M. Abrams M. Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 2002; 159: 122–129
8. Posternak MA, Miller I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using waiting-list control groups. Journal of Affective Disorders 2001; 66: 139–146
9. Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment 1, 1998; Article 0002a. http://journals.apa.org/prevention/volume1/pre0010002a.html
10. Kaptchuk T. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Annals of Internal Medicine 2002; 136: 817–825
11. McKay D, Schare ML. The effects of alcohol and alcohol expectancies on subjective reports and physiological reactivity: a meta-analysis. Addictive Behaviors 1999; 24: 633–647
12. Mitchell SH, Laurent CL, de Wit H. Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. Psychopharmacology 1996; 125: 371–378
13. McPherson K, Britton AR, Wennberg JE. Are randomised controlled trials controlled? Patient preferences and unblind trails. Journal of the Royal Society of Medicine 1997; 90: 652–656
14. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elking I, et al Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH. Treatment of Depression Collaborative Research Program. American. Journal of Psychiatry 1991; 148: 997–1008
15. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infraction in women. Journal of the American Medical Assocation 1990; 270: 742–744
16. Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H. The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technology Assessment 1998; 3: 3
17. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996; 312: 345–349
18. Di Blasi Z, Harkness E, Ernst E, Georgion A, Keijenen J. Influence of context effects on health outcomes: a systematic review. Lancet 2001; 357: 757–762
19. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305: 1198–1202
20. Bachar E. Psychotherapy — an active agent: assessing the effectiveness of psychotherapy and its curative factors. Israel Journal of Psychiatry and Related Sciences 1998; 35: 128–135
21. Carlozzi AF, Bull KS, Stein LB, Roy K, Barnes L. Empathy and practice: a survey of psychologists and counsellors. Journal of Psychology 2002; 136: 161–170
22. Jenkins V, Fallowfield L. Can communication skills training alter physicians' beliefs and behaviour in clinics? Journal of Clinical Oncology 2002; 20: 765–769
23. Thomas KB. General practice consultations: is there any point in being positive? BMJ 1987; 294: 1200–1202
24. Wheatley D. Influence of doctors' and patients' attitudes in the treatment of neurotic illness. Lancet 1967; 2: 1133–1135
25. Cruz M, Pincus HA. Research on the influence that communication in psychiatric encounters has on treatment. Psychiatric Services 2002; 53: 1253–1265
26. Horvath AO, Luborksky L. The role of the therapeutic alliance in psychotherapy. Journal of Consulting and Clinical Psychology 1993; 61: 561–575
27. Frank A, Gunderson JG. The roles of the therapeutic alliance in the treatment of schizophrenia. Archives of General Psychiatry 1990; 47: 228–236
28. Weiss M, Gaston L, Propst A, Wisebord S, Zicherman V. The role of the alliance in the pharmacological treatment of depression. Journal of Clinical Psychiatry 1997; 58: 196–204
29. Stewart MA. Effective physician-patient communication and health outcomes: a review. Canadian Medical Association Journal 1995; 152: 1423–1433
30. Starfield B, Wray C, Hess K, Gross R, Birk PS, D'Lugoff BC. The influence of patient-practitioner agreement on outcome of care. American Journal of Public Health 1981; 71: 127–131
31. Andrews G. Placebo response in depression: bane of research, boon to therapy. British Journal of Psychiatry 2001; 178: 192–194
32. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978; 1: 848–851
33. Schapira K, McClelland HA, Griffiths NR, Newell DJ. A study on the effects of tablet colour on the treatment of anxiety states. BMJ 1970; 1: 446–469
34. Branthwaite A, Cooper P. Analgesic effects of branding in treatment of headache. BMJ 1981; 282: 1576–1578
35. De Craen AJ, Moerman DE, Heisterkamp SH, Tijgat GN, Tijssen JG, Kleijnen J. Placebo effect in the treatment of duodenal ulcer. British Journal of Clinical Pharmacology 1999; 48: 853–860
36. Moncrieffe J, Wessley S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry 1998; 172: 227–231
37. Kwan J, Sandercock P. In-hospital care pathways for stroke. Cochrane Database Systematic Reviews CD002924; 2002
38. Sulch D, Melbourn A, Perez I, Kalra L. Integrated care pathways and quality of life on a stroke rehabilitation unit. Stroke 2002; 33: 1600–1604
39. Falconer JA, Roth EJ, Sutin JA, Strasser DC, Chang RW. The critical path method in stroke rehabilitation: lessons from an experiment in cost containment and outcome improvement. Quality Review Bulletin 1993; 19: 8–16
40. Bilia AR, Gallon S, Vincieri FF. St John's Wort and depression: efficacy, safety and tolerability: an update. Life Sciences 2002; 70: 3077–3096
41. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 2002; 59: 313–919
42. Lawler DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-analysis of randomised controlled trials. BMJ 2001; 322: 763–767
43. George MS, Nahas Z, Kozel FA, Goldman J, Molloy M, Oliver N. Improvement of depression following transcranial magnetic stimulation. Current Psychiatry Reports 1999; 1: 114–124
44. Partonen T, Partinen M. Light treatment for seasonal affective disorder: theoretical considerations and clinical implications. Acta Psychiatrica Scandinavica Supplementum 1994; 377: 41–45